A non-invasive stem cell delivery system using proprietary protein to repair damaged hearts

TargaCell is an early-stage biopharmaceutical company focused on repairing organ damage caused by disease processes to reverse disease, recover function, and restore quality of life. We achieve this through improved non-invasive, simple intravenous injection of our products, which provide targeted delivery of a second simple injection of regenerative cells to specific organs, thereby enhancing damaged tissue repair. The Company is developing first-in-class biologic therapeutics based on the characteristics of naturally occurring and chemically modified proprietary protein preparations and their innate ability to bind specifically with stem cells and block extraneous (Off-target) organ binding sites that trap them, preventing migration to tissues needing repair.